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RemodelingAbstract Background: Left ventricular remodeling (LVR) after myocardial infarction (MI) is
associated with adverse cardiovascular events. Left atrial volume index (LAVI) was emerged as a
prognostic factor for cardiovascular outcome. The aim of the study was to assess the value of
measuring LAVI at discharge as a predictive factor for the development of LVR after anterior
ST-elevation MI (STEMI) treated with primary percutaneous coronary intervention (PPCI).
Methods: The study included 100 consecutive patients with ﬁrst anterior STEMI successfully
treated with primary percutaneous coronary intervention (PPCI). Echocardiographic evaluation
was performed at the time of discharge and at 6 months. LVR was deﬁned as >20% increase in
LVEDVI at 6 months compared with that at discharge.
Results: The prevalence of LVRwas 31%. Patients who developedLVRhad higher LVESVI at base-
line, lower EF%, higher WMSI, higher LAVI, and longer time to perfusion. Multivariable logistic
regression analysis showed that LAVI was the only predictive factor for LVR (p= 0.003, 95%
CI = 1.87–19.7). ROC curve analysis showed that LAVI was predictive for LVRwith a cut-off value
38 ml/m2 (sensitivity 96.8% and speciﬁcity 77%, p= 0.001, 95% CI = 0.93–0.99).
Conclusion: LAVI is a simple and non-invasive echocardiographic marker that can predict the devel-
opment of LVR in patients with anterior STEMI treated with PPCI.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of
Cardiology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Left ventricular remodeling (LVR) following myocardial
infarction (MI) includes complex alternations in the architec-
ture of the left ventricle involving both the infarcted and
non-infarcted areas.1–4These changes manifest clinically as changes in the chamber
size, shape and function.3 Progressive post-infarction left
ventricular (LV) dilatation is associated with increased
cardiovascular death5 and the development of chronic heart
failure.2,6
Mechanical reperfusion using primary percutaneous coro-
nary intervention (PPCI) was associated with reduction in
the infarct size and preservation of LV function resulting in
an improved in-hospital survival.7
Table 1 Baseline clinical characteristics.
+ve remodeling
(N= 31, 31%)
ve remodeling
(N= 69, 69%)
P
value
N % N %
Age (year) 57.4 ± 7.6 years 60.6 ± 8.7 years 0.09
Male 24 77.4 55 79.7 0.7
Hypertension 16 51.6 29 42.0 0.3
Dyslipidemia 11 32.5 29 42.0 0.5
Diabetes mellitus 7 22.6 16 23.2 0.49
Smoker 10 32.3 21 30.4 0.8
Family history of
premature CAD
4 12.9 6 8.7 0.5
BSA 1.95 ± 0.16 1.90 ± 0.16 0.2
Major medications
Beta-blocker 28 90.3 63 91.3 0.7
ACEI or ARB 30 96.7 66 95.6 0.2
Statin 29 93.5% 65 94.2 0.6
Spironolactone 29 93.5% 64 92.7 0.4
CAD= Coronary artery disease. ACEI = angiotensin-converting-
enzyme inhibitor. ARB= Angiotensin II receptor blocker.
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diastolic dysfunction.8 During ventricular diastole, the left
atrium is directly exposed to the left ventricular pressure;
therefore the left atrial size is affected by changes in the LV
diastolic ﬁlling pressure.9,10 So, the left atrial volume increases
with increasing severity of LV diastolic dysfunction.11
Left atrial volume index (LAVI) was associated with
adverse events after myocardial infarction.12
The aim of this study was to determine the value of measur-
ing LAVI at discharge as a predictor of LVR in patient with
anterior (ST elevation MI) STEMI treated with PPCI.
2. Methods
 Study population:
Consecutive 100 patients with recent ﬁrst STEMI who
underwent successful PPCI in Tanta University, cardiology
department were prospectively enrolled in the study.
The study inclusion criteria were as follows: (1) conﬁrmed
ﬁrst acute STEMI based on the presence of typical angina pain
more than 30 min, new ST-segment elevation at J point in 2 or
more contiguous chest leads P0.2 mV, and elevation in
troponin or ck-MB and (2) onset of symptoms <12 h before
hospital admission.
The exclusion criteria were as follows: (1) Unsuccessful
PPCI (residual stenosis >30% and or thrombolysis in myocar-
dial infarction (TIMI) ﬂow < III). (2) Atrial ﬁbrillation or
ﬂutter. (3) Poor echogenic window. (4) Patients with mitral
stenosis or more than mild mitral regurgitation. (5) Prior
MI. (6) Cardiomyopathy. (7) Reinfarction during follow up
course. (8)Prior Coronary artery bypass grafting (CABG) or
percutaneous coronary intervention (PCI).
 Angiographic procedure:
Coronary angiography and percutaneous coronary inter-
vention were done through the femoral approach. All patients
received the following regimen: (1) Clopidogrel 300–600 mg
loading dose orally followed by maintenance dose of 75 mg/day.
(2) Aspirin 300 mg followed by 81–325 mg/day. (3) During
the procedure patients received unfractionated heparin
(100 IU/kg), and the dose was reduced to (70 IU/kg) in case
of administration of glycoprotein IIb/IIIa inhibitor (eptiﬁ-
batide). (4) All patients received FDA approved bare metal
stents (BMS).
At the end of the procedure TIMI ﬂow rate13 and myocar-
dial blush grade (MBG)14 were assessed.
 Echocardiographic evaluation:
All patients underwent two dimensional transthoracic
echocardiographic and Doppler studies using the commercially
available GE Vivid 7 echocardiograph with 2.5 MHz trans-
ducer and echocardiographic evaluation was performed at
the time of discharge and after 6 months. At discharge,
echocardiography was done to evaluate LV ejection fraction
(EF), LV end-systolic volume, LV end diastolic volume (using
biplane method of disks). LV volume indices were measured by
dividing the volume by the body surface area (BSA).15 Wall
motion score index (WMSI) was obtained in all patients, the
LV was divided into 16-segments model, and the score for eachsegment was graded according to the following system: nor-
mal, 1; hypokinesia, 2; akinesia, 3; dyskinesia, 4. The total wall
motion score (WMS) was obtained by adding the score for
each segment. The WMSI was calculated by dividing the total
wall motion score by 16.16
From the trans-mitral ﬂow proﬁle, the E and A waves peak
velocities were calculated. Doppler tissue imaging of the mitral
annulus was performed in the apical 4 chamber view using
1- to 2-mm sample volume placed in the septal mitral valve
annulus. The value of e` was measured and E/e` was obtained.17
Left atrial volume was measured in the apical 4-chamber
view at the ventricular end-systole from the frame preceding
mitral valve opening using the biplane methods of disks, left
atrial borders were traced using planimetry excluding pul-
monary veins and left atrial appendages, and left atrial volume
index was calculated by dividing LAV by (BSA).18
At 6 month follow up 2D echocardiography was repeated
to evaluate LVEDVI, LVESVI and EF. Left ventricular
remodeling was deﬁned as >20% increase in LVEDVI at
6 months compared with that at discharge.1
3. Results
One hundred patients with ﬁrst anterior wall STEMI, who
were treated with PPCI were included in the study.
The study population was divided into two groups accord-
ing to the presence or absence of LVR. The ‘‘+ve remodeling’’
group included 31(31%) patients who developed LVR and the
‘‘ve remodeling’’ group included 69(69%) patients who did
not develop LVR.
3.1. Baseline clinical characteristics
Neither groups showed any signiﬁcant differences regarding
age, sex, BSA, hypertension, dyslipidemia, diabetes mellitus
nor family history of premature coronary artery disease.
Both groups did not differ regarding major medications pre-
scribed at discharge (Table 1).
Table 2 Baseline echocardiographic characteristics.
+ve remodeling
(N= 31, 31%)
ve remodeling
(N= 69, 69%)
P
value
ESVI – at baseline
(ml/m2)
47.8 ± 15.75 36.6 ± 9.8 0.001*
EDVI – at
baseline (ml/m2)
87.5 ± 16.2 81.8 ± 12.3 0.05
EF% 48.9 ± 6.8 53.6 ± 5.2 0.002*
Left atrium volume
index (ml/m2)
42.9 ± 3.7 34.33 ± 3.9 0.0001*
Wall motion score
index
1.58 ± 0.25 1.42 ± 0.21 0.001*
Peak E (m/s) 0.732 ± 0.1 0.73 ± 0.1 0.9
Peak A (m/s) 0.777 ± 0.1 0.78 ± 0.11 0.8
E/e0 ratio 11.2 ± 2.47 10.94 ± 1.47 0.6
ESVI = end-systolic volume index. EDVI = end-diastolic volume
index. EF = Ejection fraction. E: peak mitral valve ﬂow velocity
during the early rapid ﬁlling phase; A: peak mitral valve ﬂow
velocity during atrial contraction. E/e0, the ratio of early transmi-
tral velocity to the early mitral annular velocity.
* Signiﬁcant P value.
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Regarding the baseline Echocardiographic characteristics,
both groups did not differ with respect to LVEDVI at baseline,
peak E, peak A, or E/e0 ratio. LVESVI at baseline, LAVI and
WMSI, were signiﬁcantly higher and EF% was signiﬁcantly
lower, in the ‘‘+ve remodeling’’ group (p= 0.001, 0.0001,
0.001 and 0.002 respectively) (Table 2).Table 3 Six-month follow-up echocardiographic characteristics.
+ve remodeling (N= 31, 31%
LVESVI-6 month (ml/m2) 57.36 ± 19
LVEDVI-6 month (ml/m2) 109.3 ± 22
EF-6 month (ml/m2) 48.5 ± 6.2
ESVI = end-systolic volume index. EDVI = end-diastolic volume index.
* Signiﬁcant P value.
Table 4 Angiographic characteristics.
+ve remodeling (N= 31, 31%
1 9 29.0%
2 17 54.9%
3 5 16.1%
RD 2.6 ± 0.55
Stent length 22.9 ± 4.8
Stent diameter 3.17 ± 0.37
Time of perfusion (mins) 254.9 ± 123
G IIb/IIIa inhibitors 25 (80.6%)
Thrombus aspiration 12 (38.7%)
MB grade 0 2 (6.4%)
1 6 (19.4%)
2 10 (32.3%)
3 13(41.9%)
RD= reference diameter. G IIb/IIIa inhibitors = glycoprotein IIb/IIIa
* Signiﬁcant P value.The echocardiographic measurements at 6-month follow-
up are shown in Table 3.
3.3. Angiographic characteristics
There was no signiﬁcant differences between both groups
regarding, the number of diseased vessels, rate of use of G
IIb/IIIa inhibitors, rate of use of thrombus aspiration device,
reference vessel diameter, stent length or stent diameter. The
time to perfusion was signiﬁcantly longer in the ‘‘+ve remod-
eling’’ group (P= 0.01) (Table 4).
Multivariable logistic recession analysis to assess factors
predictive of LVR included LVESVI, LAVI, EF, WMSI and
time to perfusion, and showed that LAVI was the only predic-
tive factor for LVR (odds ratio = 6.07, 95% conﬁdence inter-
val, 1.87–19.7) (Table 5).
Roc curve analysis showed that LAVI was predictive for
LVR with a cut-off value 38 with sensitivity 96.8% and speci-
ﬁcity 77% (Fig. 1).
4. Discussion
The beneﬁts of PPCI in patients with STEMI have been related
to the achievement of early patency of the infarct related artery
leading to better myocardial salvage compared with throm-
bolytic treatment.19
The favorable effects of the early reperfusion limit the
remodeling process or at least attenuate its effects on the left
ventricular shape and geometry resulting in improved
survival.20,21
LVR occurs in a relevant proportion of patients despite
successful treatment with PPCI and is an important predictor) ve remodeling (N= 69, 69%) p-value
37.4 ± 10 0.001*
78.79 ± 19 0.01*
54.5 ± 5.3 0.001*
EF = Ejection fraction.
) ve remodeling (N= 69, 69%) P value
24 34.8%
25 36.2%
20 29%
2.7 ± 0.4 0.4
21.5 ± 5.3 0.1
3.13 ± 0.35 0.975
202 ± 87.9 0.01*
57(84%) 0.7
25(36.2%) 0.8
7 (10.1%)
27 (39.1%)
14 (20.4%) 0.17
21(30.4%)
inhibitor. MB= myocardial blush.
Table 5 Multivariable logistic regression analysis.
Odds
ratio
p-value 95% conﬁdence
interval for odds
ratio
Time of perfusion 1.006 0.31 (0.99–1.01)
LVESVI 1.46 0.08 (0.98–1.33)
Ejection fraction 1.06 0.6 (0.79–1.43)
Left atrium volume index 6.07 0.003* (1.87–19.7)
Wall motion score index 29 0.16 (0.248–3395)
* Signiﬁcant P value.
ROC curve
Figure 1 Roc curve shows that the cutoff value of Left atrium
volume index (LAVI) is 38 (ml/m2) with Sensitivity (96.8%) and
speciﬁcity (77%). With area under the curve is 0.956 which means
that LAVI is signiﬁcantly a discriminative tool to detect remod-
eling (p= 0.001) with (95% C.I) = (0.93–0.99).
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identifying patients who are prone to develop progressive pos-
infarction left ventricular dilatation who are at increased risk
to have adverse cardiovascular events, may have important
therapeutic implication.
Many factors have been studied in previous studies to
predict LVR.6,22–25 This study was undertaken to evaluate
the value of measuring LAVI (which is a simple and non-
invasive echocardiographic marker) at discharge as a predic-
tive factor for the development of LVR after anterior STEMI.
Left atrial enlargement becomes a powerful predictor of
long term outcome, and left atrial dilatation has been shown
to predict both all-cause and cardiovascular mortality11,26–28
atrial ﬁbrillation29–33 and heart failure.34,35 Left atrial dilata-
tion was also evaluated in certain groups of patients like thosewith ischemic,36 dilated,37,38 or hypertrophic cardiomyopa-
thy,39 atrial arrhythmias,40 acute myocardial infarction12,41–43
and in patients with asymptomatic severe aortic stenosis.44
In the present study LVR occurred in 31% of patients
despite successful treatment with PPCI, a rate close to that
published in previous studies.1,21
Our data showed that patients with LVR have higher
LVESVI at baseline, lower EF%, higher WMSI, higher
LAVI, and longer time to perfusion.
Multivariable logistic regression analysis showed that
LAVI was the only predictive factor for LVR. ROC curve
analysis showed that LAVI was predictive of LVR with a
cut-off value 38 with sensitivity 96.8% and speciﬁcity 77%.
The clinical usefulness of LAVI at discharge as a predictive
factor for LVR after anterior STEMI may be explained by the
fact that LVR is associated with progression of diastolic dys-
function. Deterioration of diastolic dysfunction is associated
with a rise in LVEDP.8 As LAVI is inﬂuenced by LV ﬁlling
pressure, it may be a powerful predictor for the development
of LVR.
Furthermore, in response to decreased LV compliance, LA
pressure rises, leading to increased LA wall tension. The secre-
tion of cardiac peptides increases in response to both LA
stretch and increased LV pressure.45
5. Conclusion
The present study demonstrates that LAVI may predict LVR
after successful PPCI of anterior STEMI. Therefore measure-
ment of LAVI at discharge could emerge as a simple tool to
risk stratify and guide therapy in patients with anterior
STEMI.
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